Real-World Evidence (RWE) is transforming pharmaceutical research.
Unlike clinical trials, which take place under highly controlled conditions, RWE is generated from Real-World Data (RWD) collected in everyday medical practice.
This makes it possible to capture the true complexity of patient care and treatment outcomes.
RWE delivers critical value by:
As regulators, payers, clinicians, and patients increasingly embrace RWE, it has become a powerful driver of innovation, better care, and smarter healthcare decisions worldwide.
Real-World Evidence empowers Medical Affairs with credible, real-life insights that drive strategy, strengthen engagement with clinicians, and demonstrate value for patients. By leveraging nationwide health data and real-world studies, RWE provides a deeper understanding of patient journeys, treatment effectiveness, and unmet needs. This knowledge enables Medical Affairs teams to communicate more effectively with KOL, support evidence-based decision making, and ultimately contribute to improved healthcare outcomes and market access success.
To know more about our services for medical affairs ➜
Turn real-world data into compelling value stories for pricing and reimbursement.
We analyze claims, registries, and EHR data to generate actionable insights that reveal unmet needs, real-world treatment performance, and economic value — quantifying disease burden, measuring effectiveness, and assessing healthcare costs.
Stronger evidence, stronger narratives — giving you a clear advantage in payer negotiations and Market Access strategy.
We help pharma and MedTech companies unlock the full potential of the largest US claims databases — including Optum Clinformatics®, IBM MarketScan®, Medicare/Medicaid, and Flatiron Health . By transforming millions of real-world patient journeys into actionable insights, we enable our partners to understand treatment patterns, measure real-world effectiveness, and demonstrate economic and clinical value. Our advanced analytics turn complex data into strategic evidence that supports US Market Access, HEOR, and regulatory decision-making — empowering teams to move faster from data to impact.
Real-world studies now supports far more than descriptive insights. Through advanced causal designs—such as Target Trial Emulation (TTE), external control arms (ECA), and modern propensity and weighting methods—we generate evidence that meets regulatory and payer expectations. These approaches strengthen causal interpretation, reduce bias, and provide robust answers to complex clinical and real-world questions.